The mRNA Patent and Competitive Landscape: Pioneers, Litigation Outlook and Big Pharma's Next Moves (Part III) | Rothwell, Figg, Ernst & Manbeck, P.C.
Here, in our final post, we provide an analysis of the current landscape and offer conclusions. Moderna, BioNTech and CureVac –Leading Pioneers The three largest and best-positioned players in the mRNA space are currently Moderna, BioNTech and CureVac, each having very large patent estates, 11-figure market caps, double-digit candidates in their pipelines, years of development work and accumulated know-how under their belts, and key licenses and other strategic alliances in place for the manufacture, development, and commercialization of mRNA-based products. Moderna and BioNTech (with Pfize...
Source: jdsupra.com